Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/9945
Title: | Comorbidities and their impact on chronic obstructive pulmonary disease | Authors: | Dursunoğlu, Neşe. Köktürk, N. Baha, A. Bilge, A.K. Börekçi, Ş. Çiftçi, F. Karadağ, M.G. |
Keywords: | Comorbidity COPD C reactive protein calcium denosumab fibrinogen ghrelin growth hormone interleukin 1beta interleukin 6 megestrol parathyroid hormone[1-34] testosterone tumor necrosis factor vitamin D aging anemia anxiety Article asthma body mass chronic obstructive lung disease clinical trial (topic) comorbidity depression diabetes mellitus emphysema family history gastroesophageal reflux heart failure human hypertension ischemic heart disease lung cancer lung diffusion capacity lung fibrosis malnutrition metabolic syndrome X musculoskeletal disease obesity osteoporosis respiratory system sleep disorder smoking vitamin D deficiency Cardiovascular Diseases disease management health status Lung Neoplasms Musculoskeletal Diseases Pulmonary Disease, Chronic Obstructive quality of life cardiovascular disease complication lung tumor Diabetes Mellitus Disease Management Health Status Humans Quality of Life |
Publisher: | Ankara University | Abstract: | Chronic obstructive pulmonary disease (COPD) is a complex disease that is associated with devastating outcomes resulting from lung involvement and several comorbidities. Comorbidities could impact on symptomology, quality of life, the complications, the management, economic burden and the mortality of the disease. The importance of comorbidities originates from their impact on the outcome of COPD. The most frequent comorbidities in COPD are cardiovascular, endocrinological, musculoskeletal, phycological disorders and lung cancer. Almost 50% of the COPD patients have 3 or more comorbidities. The recent Global Initiative of Obstructive Lung Disease (GOLD) Guideline suggested proactive search and the treatment of the comorbidities. However, there is no certain evidence demonstrating that active treatment of comorbidities improve the outcomes of COPD. However, it is well known that several comorbidities such as cardiovascular disease and lung cancer have greater impact on mortality caused by COPD. Several studies have shown that Charlson Comorbidity index or more recenty COPD Specific Comorbidity Index (COTE) has been found to be related with mortality of COPD. This concise review intended to summarize the most frequent comorbidities in association with their impact on COPD. © 2016, Ankara University. All rights reserved. | URI: | https://hdl.handle.net/11499/9945 https://doi.org/10.5578/tt.2245 |
ISSN: | 0494-1373 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
neşe dursunoğlu.pdf | 99.07 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
7
checked on Sep 30, 2024
WEB OF SCIENCETM
Citations
9
checked on Sep 24, 2024
Page view(s)
48
checked on Aug 24, 2024
Download(s)
20
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.